View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Re...

POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiophar...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 25, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Tidewater Inc: 1 director

A director at Tidewater Inc bought 27,000 shares at 39.642USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results

Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results - Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division - Enzo Life Sciences reports revenue of $7.5 million, with Jan-23 revenue of $3.6M as the second highest monthly revenue in over 10 years FARMINGDALE, NY, March 21, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23). Enzo Biochem will not b...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 18, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

OXY OCCIDENTAL PETROLEUM CORPORATION
WAFD WASHINGTON FEDERAL INC.
VLY VALLEY NATIONAL BANCORP
UMBF UMB FINANCIAL CORPORATION
UAL UNITED AIRLINES HOLDINGS INC.
SWX SOUTHWEST GAS HOLDINGS INC.
RRGB RED ROBIN GOURMET BURGERS INC.
QCRH QCR HOLDINGS INC.
PSA PUBLIC STORAGE
PGRE PARAMOUNT GROUP INC.
PACW PACWEST BANCORP
OEC ORION ENGINEERED CARBONS SA
OCFC OCEANFIRST FINANCIAL CORP.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTD METTLER-TOLEDO INTERNATIONAL INC.
HASI HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GBCI GLACIER BANCORP INC.
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
DVN DEVON ENERGY CORPORATION
CVBF CVB FINANCIAL CORP.
CNC CENTENE CORPORATION
CCNE CNB FINANCIAL CORP. (PENNSYLVANIA)
AXTA AXALTA COATING SYSTEMS LTD.
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
WMB WILLIAMS COMPANIES INC.
SPOK SPOK HOLDINGS
INBK FIRST INTERNET BANCORP
SMMF SUMMIT FINANCIAL GROUP INC.
BWFG BANKWELL FINANCIAL GROUP
FBK FB FINANCIAL CORPORATION
JELD JELD-WEN HOLDING INC.
GNTY GUARANTY BANCSHARES INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
BY BYLINE BANCORP
VST VISTRA CORP.
MCB METROPOLITAN BANK HOLDING
MPB MID PENN BANCORP INC.
CCB COASTAL FINANCIAL
OPBK OP BANCORP
CBNK CAPITAL BANCORP
SCHW THE CHARLES SCHWAB CORPORATION
LARK LANDMARK BANCORP INC.
RILY B. RILEY FINANCIAL
SMMT SUMMIT THERAPEUTICS INC
GEG GREAT ELM GROUP INC
VERA VERA THERAPEUTICS INC
TRST TRUSTCO BANK CORP NY
TBBK THE BANCORP
FRST INC.
PDLB PRIMIS FINANCIAL CORP
PONCE FINANCIAL GROUP INC.
 PRESS RELEASE

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp Significant value unlocked for Enzo shareholders with continued focus on remaining businesses. FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs). The transaction between two leading global life sciences companies follows several steps initiated by Enzo in 2022 to advance the company’s “focused return” initiative to maximize shareholder ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: March 14, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: March 13, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 11, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clini...

POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays. “POINT...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: March 6, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 4, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: February 27, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: February 24, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: February 23, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Treasury Yields Reversing Higher Our outlook remains neutral and we continue to expect the 4165-4200 level to cap upside on the S&P 500. With that said, there has yet to be any meaningful deterioration, and a move up to test the August 2022 highs in the 4300-4325 range is not out of the question. Either way, we continue to preach caution and believe that upside is limited on the market indexes. Treasury yields are starting to reverse above multi-month downtrends, and we are monitoring for simil...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch